TY - JOUR
T1 - Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor
T2 - real-world data
AU - van Kuijk, Arno W. R.
AU - Nurmohamed, Mike T.
AU - Siebert, Stefan
AU - Bergmans, Paul
AU - de Vlam, Kurt
AU - Gremese, Elisa
AU - Joven-Ibáñez, Beatriz
AU - Korotaeva, T. V.
AU - Lavie, Frederic
AU - Sharaf, Mohamed
AU - Noël, Wim
AU - Theander, Elke
AU - Smolen, Josef S.
AU - Gossec, Laure
AU - van der Horst-Bruinsma, Irene E.
N1 - Funding Information: This study was sponsored by Janssen. Medical writing and editorial support were provided by Olga Ucar and Ella Palmer of inScience Communications, Springer Healthcare Ltd, UK, and funded by Janssen. Publisher Copyright: © 2023 The Author(s). Published by Oxford University Press on behalf of the British Society for Rheumatology.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Objective: Investigate effects of gender on disease characteristics and treatment impact in patients with PsA. Methods: PsABio is a non-interventional European study in patients with PsA starting a biological DMARD [bDMARD; ustekinumab or TNF inhibitor (TNFi)]. This post-hoc analysis compared persistence, disease activity, patient-reported outcomes and safety between male and female patients at baseline and 6 and 12 months of treatment. Results: At baseline, disease duration was 6.7 and 6.9 years for 512 females and 417 males respectively. Mean (95% CI) scores for females vs males were: clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA), 32.3 (30.3, 34.2) vs 26.8 (24.8, 28.9); HAQ-Disability Index (HAQ-DI), 1.3 (1.2, 1.4) vs 0.93 (0.86, 0.99); total PsA Impact of Disease-12 (PsAID-12) score, 6.0 (5.8, 6.2) vs 5.1 (4.9, 5.3), respectively. Improvements in scores were smaller in female than male patients. At 12 months, 175/303 (57.8%) female and 212/264 (80.3%) male patients achieved cDAPSA low disease activity, 96/285 (33.7%) and 137/247 (55.5%), achieved minimal disease activity (MDA), respectively. HAQ-DI scores were 0.85 (0.77, 0.92) vs 0.50 (0.43, 0.56), PsAID-12 scores 3.5 (3.3, 3.8) vs 2.4 (2.2, 2.6), respectively. Treatment persistence was lower in females than males (P ≤ 0.001). Lack of effectiveness was the predominant reason to stop, irrespective of gender and bDMARD. Conclusions: Before starting bDMARDs, females had more severe disease than males and a lower percentage reached favourable disease states, with lower persistence of treatment after 12 months. A better understanding of the mechanisms underlying these differences may improve therapeutic management in females with PsA. Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov,
AB - Objective: Investigate effects of gender on disease characteristics and treatment impact in patients with PsA. Methods: PsABio is a non-interventional European study in patients with PsA starting a biological DMARD [bDMARD; ustekinumab or TNF inhibitor (TNFi)]. This post-hoc analysis compared persistence, disease activity, patient-reported outcomes and safety between male and female patients at baseline and 6 and 12 months of treatment. Results: At baseline, disease duration was 6.7 and 6.9 years for 512 females and 417 males respectively. Mean (95% CI) scores for females vs males were: clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA), 32.3 (30.3, 34.2) vs 26.8 (24.8, 28.9); HAQ-Disability Index (HAQ-DI), 1.3 (1.2, 1.4) vs 0.93 (0.86, 0.99); total PsA Impact of Disease-12 (PsAID-12) score, 6.0 (5.8, 6.2) vs 5.1 (4.9, 5.3), respectively. Improvements in scores were smaller in female than male patients. At 12 months, 175/303 (57.8%) female and 212/264 (80.3%) male patients achieved cDAPSA low disease activity, 96/285 (33.7%) and 137/247 (55.5%), achieved minimal disease activity (MDA), respectively. HAQ-DI scores were 0.85 (0.77, 0.92) vs 0.50 (0.43, 0.56), PsAID-12 scores 3.5 (3.3, 3.8) vs 2.4 (2.2, 2.6), respectively. Treatment persistence was lower in females than males (P ≤ 0.001). Lack of effectiveness was the predominant reason to stop, irrespective of gender and bDMARD. Conclusions: Before starting bDMARDs, females had more severe disease than males and a lower percentage reached favourable disease states, with lower persistence of treatment after 12 months. A better understanding of the mechanisms underlying these differences may improve therapeutic management in females with PsA. Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov,
KW - PsA
KW - bDMARD
KW - disease activity
KW - disease impact
KW - gender
KW - persistence
KW - real-world
UR - http://www.scopus.com/inward/record.url?scp=85173563588&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/rheumatology/kead089
DO - https://doi.org/10.1093/rheumatology/kead089
M3 - Article
C2 - 36810788
SN - 1462-0324
VL - 62
SP - 3382
EP - 3390
JO - Rheumatology (Oxford, England)
JF - Rheumatology (Oxford, England)
IS - 10
ER -